Bio-Path Holdings, Inc.

128 articles with Bio-Path Holdings, Inc.

• Bio-Path Holdings to Announce First Quarter 2021 Financial Results on May 14, 2021

  5/7/2021

  Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, May 14, 2021 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2021 and to provide a business overview.

• Bio-Path Announces Publication in Biomedicines

  4/22/2021

  Peer Reviewed Manuscript Highlights Challenges of Antisense Oligonucleotide Drug Delivery and Benefits of Prexigebersen

• Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia

  4/5/2021

  Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announced the successful completion of the safety run-in of the Stage 2 of the Phase 2 clinical study of prexigebersen, a liposomal Grb2 antisense, for the treatment of acute myeloid leukemia, in combination with frontline therapies, decitabine and venetoclax, in acute myeloid leukemia patients.

• Bio-Path Holdings to Present at the 2021 American Association for Cancer Research Annual Meeting

  3/11/2021

  Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, announced an upcoming virtual poster presentation at the 2021 American Association for Cancer Research Annual Meeting, taking place April 10-15 and May 17-21, 2021.

• Bio-Path Holdings, Inc. Announces Pricing of $13.0 Million Public Offering of Common Stock

  2/16/2021

  Bio-Path Holdings, Inc. announced the pricing of its previously announced public offering for the offering of 1,710,600 shares of common stock at a price to the public of $7.60 per share, for aggregate gross proceeds to the Company of approximately $13.0 million, before deducting the fees and estimated offering expenses payable by the Company.

• Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock - Feb 13, 2021

  2/13/2021

  Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in a public offering.

• Bio-Path Holdings Reports Third Quarter 2020 Financial ResultsConference Call to be Held Today at 8:30 A.M. ET

  11/13/2020

  Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, announced its financial results for the third quarter ended September 30, 2020 and provided an update on recent corporate developments.

• Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020

  11/6/2020

  Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 13, 2020 at 8:30 a.m. ET to report financial results

• Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers

  10/22/2020

  Growing Patent Estate Creates Value and Supports Key Combination Therapies

• Bio-Path Holdings to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

  9/9/2020

  Bio-Path Holdings, Inc. announced that Peter H. Nielsen, Chief Executive Officer, will present a corporate overview at the upcoming virtual H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020 at 11:30 a.m. ET.

• Bio-Path Holdings Reports Second Quarter 2020 Financial ResultsConference Call to be Held Today at 8:30 A.M. ET

  8/14/2020

  Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, announced its financial results for the second quarter ended June 30, 2020 and provided an update on recent corporate developments.

• Bio-Path Holdings Announces First Patient Dosed in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid Leukemia

  8/13/2020

  Combination of Prexigebersen, Decitabine and Venetoclax Is Expected to Have Several Potential Pathways to Registration

• Bio-Path Holdings to Announce Second Quarter 2020 Financial Results on August 14, 2020

  8/7/2020

  Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, August 14, 2020 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2020 and to provide a business overview. To access the live con

• Bio-Path Holdings Presents at 2020 American Society of Clinical Oncology Annual Meeting

  5/29/2020

  Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announces the presentation of a poster highlighting the clinical trial design of its Phase 2 study of BP1001 at the 2020 American Society of Clinical Oncology Annual Meeting, taking place virtually from May 29-31, 2020.

• Bio-Path Holdings Reports First Quarter 2020 Financial ResultsConference Call to be Held Today at 8:30 A.M. ET

  5/15/2020

  Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2020 and provided an update on recent corporate developments. “We continued to make meaningful progress throughout the first quarter across all of our promising DNAbilize

• Bio-Path Holdings to Present at the 2020 American Society of Clinical Oncology Annual Meeting

  5/13/2020

  Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, announced an upcoming virtual poster presentation at the 2020 American Society of Clinical Oncology Annual Meeting, taking place from May 29-31, 2020.

• Bio-Path Holdings to Announce First Quarter 2020 Financial Results on May 15, 2020

  5/8/2020

  HOUSTON, May 08, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, May 15, 2020 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2020 and to provide a business overview. To access the live confe

• Bio-Path Holdings Presents at 2020 American Association for Cancer Research Annual Meeting

  4/27/2020

  Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces the presentation of a poster highlighting the clinical trial design of its Phase 1 study of BP1002 at the 2020 American Association for Cancer Research (AACR) Annual Meeting being held virtually from April 27-28, 2020. The poster

• Bio-Path Holdings to Present at the 2020 American Association for Cancer Research Annual Meeting

  4/13/2020

  Bio-Path Holdings, Inc., announced an upcoming virtual poster presentation at the 2020 American Association for Cancer Research Annual Meeting, taking place from April 27-28, 2020.

• Bio-Path Holdings Appoints Ernst & Young as New Auditor

  3/11/2020

  Bio-Path Holdings, Inc. announced that the Audit Committee of the Company’s Board of Directors approved the appointment of Ernst & Young LLP as the Company’s new independent registered public accounting firm, replacing former auditor, BDO USA, LLP.